Acer Therapeutics Performance
| ACERDelisted Stock | USD 0.84 0.02 2.33% |
The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Acer Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Acer Therapeutics is expected to be smaller as well. Acer Therapeutics right now shows a risk of 0.0%. Please confirm Acer Therapeutics jensen alpha and the relationship between the value at risk and day typical price , to decide if Acer Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acer Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical and fundamental indicators, Acer Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 12.7 M |
Acer |
Acer Therapeutics Relative Risk vs. Return Landscape
If you would invest 84.00 in Acer Therapeutics on September 17, 2024 and sell it today you would earn a total of 0.00 from holding Acer Therapeutics or generate 0.0% return on investment over 90 days. Acer Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Acer, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acer Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acer Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acer Therapeutics, and traders can use it to determine the average amount a Acer Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ACER |
Based on monthly moving average Acer Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acer Therapeutics by adding Acer Therapeutics to a well-diversified portfolio.
Acer Therapeutics Fundamentals Growth
Acer Stock prices reflect investors' perceptions of the future prospects and financial health of Acer Therapeutics, and Acer Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acer Stock performance.
| Return On Equity | -4.73 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 52.01 M | |||
| Shares Outstanding | 24.46 M | |||
| Price To Earning | (7.40) X | |||
| Price To Book | 17.26 X | |||
| Price To Sales | 174.52 X | |||
| EBITDA | (24.81 M) | |||
| Cash And Equivalents | 14.47 M | |||
| Cash Per Share | 0.91 X | |||
| Total Debt | 11.86 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (30.25 M) | |||
| Earnings Per Share | (1.98) X | |||
| Total Asset | 11.62 M | |||
| Retained Earnings | (140.75 M) | |||
| Current Asset | 6.61 M | |||
| Current Liabilities | 5.62 M | |||
About Acer Therapeutics Performance
Assessing Acer Therapeutics' fundamental ratios provides investors with valuable insights into Acer Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acer Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. Acer Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Things to note about Acer Therapeutics performance evaluation
Checking the ongoing alerts about Acer Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acer Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acer Therapeutics is not yet fully synchronised with the market data | |
| Acer Therapeutics has some characteristics of a very speculative penny stock | |
| Acer Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Acer Therapeutics currently holds 11.86 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Acer Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Acer Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (26.24 M) with profit before overhead, payroll, taxes, and interest of 1.26 M. | |
| Acer Therapeutics currently holds about 14.47 M in cash with (30.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of Acer Therapeutics shares are held by company insiders |
- Analyzing Acer Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acer Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Acer Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acer Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acer Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acer Therapeutics' stock. These opinions can provide insight into Acer Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |